ETS Receives Innovative Technology Contract from Vizient for Mirragen® Advanced Wound Matrix
New Contract Provides Access to Novel ETS Bioactive Glass for Treatment of Chronic and Acute Wounds
Rolla, MO, May 7, 2024 – Engineered Tissue Solutions announced that Mirragen® Bioactive Glass has received an Innovative Technology contract from Vizient, Inc. the nation’s largest provider-driven healthcare performance improvement company. The contract was awarded based on the recommendation of Mirragen by hospital experts who serve on one of Vizient’s customer-led councils, and it signifies to Vizient provider customers unique qualities that potentially bring improvement to the healthcare industry.
Innovative Technology contracts are recommended after review and interaction with products submitted through Vizient’s Innovative Technology Program. Vizient customer-led councils identify technologies that have the potential to enhance clinical care, patient safety, healthcare worker safety or improve business operations of healthcare organizations.
“We are honored to receive this Innovative Technology contract from Vizient’s distinguished team of experts,” said Dr. Nicolas Guggenheim, CEO of ETS Wound Care LLC. “This contract underscores ETS’s dedication to advancing wound care. It enables us to broaden the accessibility of our groundbreaking product, ensuring that more healthcare providers and patients can experience the benefits of our technology.”
Mirragen is an innovative, flexible synthetic skin substitute designed to seamlessly conform to any wound bed. Its construction is meticulously engineered for biocompatibility, enhancing the body’s natural healing processes. Featuring a unique porous fiber and microsphere structure, it effectively absorbs wound exudate while maintaining an optimal moisture balance. This structure provides an excellent scaffold that supports efficient wound healing. Mirragen has demonstrated impressive clinical results across a spectrum of wounds, from simple to complex, showcasing its versatility and effectiveness in wound care.
“Our customer-led council reviewed and recommended Mirragen for an Innovative Technology contract based on its potential to make an incremental difference in health care,” said Kelly Flaharty, senior director of contract services for Vizient. “Congratulations to Engineered Tissue Solutions on receiving this contract status.”
Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with customer-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle.
###
Engineered Tissue Solutions (ETS) is an innovative company in the medical device industry, dedicated to advancing wound healing through cutting-edge borate-based bioactive glass technology. As a member of the Heraeus Group, a globally diversified family-owned technology company, ETS draws upon a legacy of excellence and innovation. Learn more about the Heraeus Group at www.Heraeus.com.